Factor-dependent cell Paterson mixed potential (FDCPmix) cells are murine, multipotent, interleukin-3 (IL-3)-dependent progenitor cells, established from long-term bone marrow cultures. They show multilineage myeloid/erythroid and osteoclast differentiation capacity in vitro. FDCPmix cells are neither immortalised, leukaemic nor transformed and have no detectable karyotypic abnormalities. To investigate the broader differentiation potential of FDCPmix cells in vivo, they were injected into murine blastocysts, and the engraftment of donor cells in developing chimaeric embryos was analysed. FDCPmix cell progeny was detected predominantly in haematopoietic tissues, and immunohistochemical analysis revealed that the majority of donor-derived cells expressed the pan-haematopoietic marker CD45. Albumin expression indicative of hepatocytes was not detectable in FDCPmix-derived cells in chimaeric foetal livers. However, analysis of foetal brains of developing embryos revealed a low frequency of neural cell adhesion molecule-positive donor cells. These results suggest that the majority of FDCPmix cells injected into blastocysts follow haematopoietic differentiation programs, but that a small number of cells can assume the expression of neural markers.

Keywords:
Developmental potentials, FDCPmix cells, Stem cells, somatic, Mouse
1.
Arahuetes, R.M., E. Sierra, J. Codesal, M.S. Garcia Barrutia, E. Arza, J. Cubero, A. Ortiz, P. Maganto (2001) Optimization of the technique to isolate fetal hepatocytes, and assessment of their functionality by transplantation. Life Sci 68: 763–772.
2.
Bonifer, C., N. Faust, H. Geiger, A.M. Müller (1998) Developmental changes in the differentiation capacity of haematopoietic stem cells. Immunol Today 19: 236–241.
3.
Cumano, A., F. Dieterlen-Lievre, I. Godin (1996) Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. Cell 86: 907–916.
4.
Dürr, M., F. Harder, A. Merkel, G. Bug, R. Henschler, A.M. Müller (2003) Chimaerism and erythroid marker expression after microinjection of human acute myeloid leukaemia cells into murine blastocysts. Oncogene 22: 9185–9191.
5.
Eglitis, M.A., E. Mezey (1997) Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci USA 94: 4080–4085.
6.
Ford, A.M., L.E. Healy, C.A. Bennett, E. Navarro, E. Spooncer, M.F. Greaves (1992) Multilineage phenotypes of interleukin-3-dependent progenitor cells. Blood 79: 1962–1971.
7.
Geiger, H., S.C. Sick, A.M. Bonifer. A.M. Müller (1998) Globin gene expression is reprogrammed in chimeras generated by injecting adult hematopoietic stem cells into mouse blastocysts. Cell 93: 1055–1065.
8.
Harder, F., R. Henschler, I. Junghahn, M.C. Lamers, A.M. Müller (2002a) Human hematopoiesis in murine embryos after injecting human cord blood-derived hematopoietic stem cells into murine blastocysts. Blood 99: 719–721.
9.
Harder, F., N. Kirchhof, S. Petrovic, C. Schmittwolf, M. Dürr, A.M. Müller (2002b) Developmental potentials of hematopoietic and neural stem cells following injection into pre-implantation blastocysts. Ann Hematol 81(suppl 2): S20–S21.
10.
Jiang, Y., B.N. Jahagirdar, R.L. Reinhardt, R.E. Schwartz, C.D. Keene, X.R. Ortiz-Gonzalez, M. Reyes, T. Lenvik, T. Lund, M. Blackstad, et al. (2002) Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41–49.
11.
Kirchhof, N., F. Harder, S. Petrovic, S. Kreutzfeldt, C. Schmittwolf, M. Dürr, J. Kirsten, B. Mühl, A. Merkel, A.M. Müller (2002) Developmental potential of hematopoietic and neural stem cells: unique or all the same? Cells Tissues Organs 171: 77–89.
12.
Medvinsky, A., E. Dzierzak (1996) Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 86: 897–906.
13.
Müller, A.M., A. Medvinsky, J. Strouboulis, F. Grosveld, E. Dzierzak (1994) Development of hematopoietic stem cell activity in the mouse embryo. Immunity 1: 291–301.
14.
Paratcha, G., F. Ledda, C.F. Ibanez (2003) The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 113: 867–879.
15.
Schmid I, Cole S.W., J.A. Zack, J.V. Giorgi (2000) Measurement of lymphocyte subset proliferation by three-color immunofluorescence and DNA flow cytometry. J Immunol Methods 235: 121–131.
16.
Spooncer, E., C.M. Heyworth, A. Dunn, T.M. Dexter (1986) Self-renewal and differentiation of interleukin-3-dependent multipotent stem cells are modulated by stromal cells and serum factors. Differentiation 31: 111–118.
17.
Terada, N., T. Hamazaki, M. Oka, M. Hoki, D.M. Mastalerz, Y. Nakano, E.M. Meyer, L. Morel, B.E. Petersen, E.W. Scott (2002) Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 416: 542–545.
18.
Vassilopoulos, G., P.R. Wang, D.W. Russell (2003) Transplanted bone marrow regenerates liver by cell fusion. Nature 422: 901–904.
19.
Wang, X., H. Willenbring, Y. Akkari, Y. Torimaru, M. Foster, M. Al-Dhalimy, E. Lagasse E., M. Finegold, S. Olson, M. Grompe (2003) Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature 422: 897–901.
20.
Ying, Q.L., J. Nichols, E.P. Evans, A.G. Smith (2002) Changing potency by spontaneous fusion. Nature 416: 545–548.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.